Tigermed

What Tigermed does

Tigermed (Hangzhou Tigermed Consulting Co., Ltd.) is a China-headquartered, publicly listed contract research organization (CRO) founded in 2004 that provides full-lifecycle clinical research services spanning preclinical development through post-marketing surveillance. The company serves global biopharmaceutical companies, Chinese innovative pharmaceutical companies, medical device and IVD manufacturers, and vaccine developers, with named enterprise customers including Merck, Lilly, GSK, 3SBio, Insilico Medicine, CanSino Biologics, Sinocelltech, and Hutchison. Revenue is generated entirely through B2B professional services contracts on a project-based pricing model with multi-year engagement horizons, sold via direct enterprise field sales teams and RFP/business enquiry channels — no public pricing tiers exist.

The platform combines an integrated proprietary technology stack — the Clinflash suite (EDC, IRT, Safety/PV, ePRO, CTMS, eTMF, eCTD), the LUX medical imaging system, the TAYA AI large model platform, and a decentralized clinical trial (DCT) platform — with operational scale of 11,000+ employees across 180+ offices in 43+ countries and 100+ subsidiaries. Service lines include preclinical medicinal chemistry, compound screening, DMPK, safety & toxicology, bioanalytical and CMC services; clinical monitoring, regulatory affairs, data management and biostatistics, site management (SMO with 4,000+ CRCs across 1,100+ sites in 150+ Chinese cities), pharmacovigilance, medical imaging, multi-region clinical trials (MRCTs), vaccine clinical trials, medical device/IVD support, and functional service provider (FSP) staffing. Therapeutic expertise covers oncology, hematology, cardiovascular, infectious diseases, cell and gene therapy, GLP-1, and radiopharmaceuticals.

Tigermed is dual-listed on the Shenzhen Stock Exchange (300347.SZ, since 2011) and the Hong Kong Stock Exchange (3347.HK, since 2019). FY2025 reported revenue of RMB 6,833 million, net new bookings of RMB 10,158 million (up 20.6% YoY), backlog of RMB 18,202 million (up 15.4% YoY), and adjusted net profit of RMB 355 million, with overseas revenue representing 46% of total. Global footprint has been built through acquisitions including Frontage Labs (2013, later IPO'd on HKSE as 1521.HK), DreamCIS (Korea, 2014), Marti Farm (Europe, 2022/2023), Medical Edge (Japan, 2023/2024), and Micron (Japan, July 2025), supplemented by organic expansion across Latin America, Africa, the Middle East, and Southeast Asia.

Name

Tigermed

Legal name

Hangzhou Tigermed Consulting Co., Ltd.

Website

https://tigermedgrp.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Tigermed is a China-headquartered, dual-listed clinical contract research organization (CRO) providing full-lifecycle drug development services — from preclinical through post-marketing — to global biopharmaceutical, medical device, and vaccine developers across 43+ countries.

Ownership category

akta.pro rank

Product category

Contract Research Organization Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

Keywords

• Clinical trial services
• Preclinical research services
• Pharmacovigilance consulting
• Medical device trials
• Regulatory affairs support

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices13 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Full-service CRO providing end-to-end clinical development services from preclinical through post-marketing phases. Services include clinical monitoring, data management, biostatistics, regulatory affairs, pharmacovigilance, medical imaging, site management (SMO), and decentralized clinical trials.
2. Preclinical Services: Preclinical research and development including medicinal chemistry, compound screening, DMPK, safety & toxicology, bioanalytical services, and CMC (Chemistry, Manufacturing and Controls) services.
3. Medical Device/IVD Services: Comprehensive regulatory and clinical trial services for medical devices and in vitro diagnostics covering regulatory affairs, R&D testing, GMP support, clinical trials, and post-marketing support.
4. Functional Service Provider (FSP): Flexible staffing solutions providing clinical research professionals including CRA, PM, CTA, RA, PV, DM and other positions to support pharmaceutical companies.
5. Digital/AI Services: AI-powered platforms and digital solutions including TAYA AI, Clinflash suite (EDC, Safety, IRT, ePRO, CTMS, eTMF, eCTD), and DCT platform generating additional service revenue.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Tigermed is a global clinical Contract Research Organization (CRO) delivering full-process drug and medical device development services from preclinical research through post-marketing. Service offerings span medicinal chemistry, DMPK, safety/toxicology, bioanalytical and CMC studies; Phase I–IV clinical monitoring, regulatory affairs, data management, biostatistics, decentralized clinical trials, site management, and multi-region clinical trials; plus integrated capabilities including medical imaging, pharmacovigilance, medical translation, central laboratory services, and functional service provider staffing for pharmaceutical, biotechnology, vaccine, and medical device/IVD clients.

Product overview

Tigermed is a leading clinical Contract Research Organization (CRO) offering a comprehensive, integrated platform for global biopharmaceutical and medical device industries. The portfolio comprises four core service areas: Preclinical Development (medicinal chemistry, compound screening, DMPK, safety & toxicology, bioanalytical, CMC), Clinical Development (monitoring, regulatory affairs, data management, DCTs, site management, medical device/IVD), Integrated Services (medical imaging, pharmacovigilance, translation, QA, central labs, FSP), and Real World Study. Key technology products include the Clinflash suite (EDC, IRT, Safety, ePRO, CTMS, eTMF, eCTD) and the TAYA AI large model platform. Tigermed supports the full drug development lifecycle from preclinical through commercialization, with therapeutic expertise spanning oncology, hematology, cardiovascular, infectious diseases, CNS, and cell/gene therapy.

Differentiator

Problem solved

Functional benefit

Brands

• Clinflash (易迪希): EDC, IRT, PV, CTMS, ePRO, eTMF, eCTD clinical trial technology platforms
• Tigerise
• Medical Edge

Products and services

• Preclinical Development Services One-stop preclinical research platform covering medicinal chemistry, compound screening, DMPK (Drug Metabolism and Pharmacokinetics), safety & toxicology, bioanalytical, and CMC (Chemistry, Manufacturing and Controls) services for pharmaceutical and biotechnology clients.
• Clinical Development Services End-to-end clinical trial services including medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, site management, and medical device/IVD support for Phase I–IV studies.
• Integrated Services Supporting capabilities including medical imaging, pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional service provider staffing, and participant management.
• Real World Study Services Real-world evidence solutions including retrospective and prospective real-world studies, post-marketing safety monitoring, health economics outcomes research, and patient management for pharmaceutical and medical device clients.
• Multi-Region Clinical Trial (MRCT) Services Cross-nation and cross-function full CRO services for international multicenter clinical trials covering 54 countries and regions in oncology, vaccine, cardiovascular disease, and other therapeutic areas.
• Vaccine Clinical Trial Services Comprehensive vaccine clinical research services from Phase I through Phase IV with experience in 70+ approved vaccines and large-scale COVID-19 vaccine trials across multiple countries.
• Medical Device / IVD Services Regulatory and clinical trial services for medical devices and in vitro diagnostic products with experience across 30+ countries and 2,100+ manufacturers.
• Site Management Organization (SMO) Services Professional Clinical Research Coordinator (CRC) services covering Phase I–IV clinical trials with 4,000+ full-time coordinators across 1,100+ clinical trial sites in 150+ Chinese cities.
• Decentralized Clinical Trials (DCT) Services Digital and decentralized clinical trial solutions featuring eConsent, TeleVisit, Direct-to-Patient supply, Risk-Based Quality Management (RBQM), eCPM, and ePAY capabilities deployed across 300+ clinical trials.
• Medical Imaging Services Comprehensive imaging evaluation services including oncology, cardiovascular, and CNS imaging with modalities such as CT, MRI, and PET, supported by Tigermed's proprietary LUX imaging system.
• Pharmacovigilance Services Global pharmacovigilance services spanning clinical trials to post-marketing for drugs, medical devices, vaccines, and cosmetics, delivered by 200+ global PV experts.
• Central Laboratory Services Global standardized testing and analysis including routine testing, biological analysis, flow cytometry, and molecular pathology services with College of American Pathologists (CAP) accreditation.
• Functional Service Provider (FSP) Services Flexible staffing solutions providing clinical research professionals including CRAs, PMs, CTAs, Regulatory Affairs, Pharmacovigilance, and Data Management personnel across 180+ worldwide locations.
• Medical Translation Services Translation services in 100+ languages covering drugs, medical devices, and regulations, combining AI-powered machine translation with expert reviewer certification (ISO 9001, ISO 17100, ISO 27001, ISO 14001).
• Remote Follow-up Center AI-based intelligent call center and follow-up services for decentralized clinical research, including hotline answering and adverse event collection via an APP-based platform for streamlined subject follow-ups.
• Clinflash EDC (Electronic Data Capture) Cloud-based electronic data capture system with 4,000+ clinical studies enabled, supporting NMPA and FDA submissions with full validation, CDISC compliance, and 21 CFR Part 11 compliance.
• Clinflash IRT (Interactive Response Technology) Randomization and trial supply management system applied to 600+ clinical research projects with complex randomization and supply chain management capabilities.
• Clinflash Safety Pharmacovigilance System Drug safety database supporting adverse event processing, reporting, and analysis with E2B R3 standard compliance for global pharmacovigilance operations.
• Clinflash ePRO (Electronic Patient-Reported Outcomes) Electronic patient-reported outcome system using mobile and cloud technology for collecting subject medication adherence and symptom information in clinical trials.
• Clinflash CTMS (Clinical Trial Management System) Clinical trial management system providing real-time project tracking, personnel management, and multi-party collaboration across the trial lifecycle.
• Clinflash eCTD (Electronic Common Technical Document) Electronic Common Technical Document system for global drug registration and submission management, supporting China NMPA and US FDA electronic submissions.
• TAYA AI Large Model Platform Self-developed AI large model platform commercialized in 2025 powering intelligent medical language services, regulatory submissions, biostatistics, and pharmacovigilance workflows for biopharmaceutical clients.

Quantifiable outcome

• 61% of China's NMPA-approved Class 1 innovative drugs since 2004 supported by Tigermed
• +4 more outcomes

Named customers12 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature11 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Hong Kong Government OASES InitiativecoreStrategic or Co-development Partner · 1 April 2026OASES (Hong Kong's health and medical innovation hub initiative) strategic enterprise partnership. Tigermed signed agreement to expand clinical trials and research partnerships through Greater Bay Area International Clinical Trial Institute and University of Hong Kong collaborations.
• HCW BiologicsminorStrategic or Co-development Partner · 1 February 2026Trimmune joint venture with WY Biotech and backing from CITIC Medical Fund and TigerMed. Joint venture holds exclusive worldwide license for HCW11-006 preclinical cancer molecule. TigerMed provides clinical development expertise and financing.
• WY BiotechminorStrategic or Co-development Partner · 1 February 2026Trimmune joint venture co-founding partner with HCW Biologics. Joint venture focused on cancer immunotherapy development combining HCW Biologics' molecule pipeline with Chinese clinical development capabilities.
• 3SBiocoreStrategic or Co-development Partner · 1 January 2026Comprehensive collaboration covering innovative drug R&D, clinical services, and industrial investment. Long-term R&D partnership reflecting growing need among local innovative pharmaceutical companies for integrated collaboration.
• Insilico MedicinecoreStrategic or Co-development Partner · 1 January 2026Collaboration connecting AI-driven drug discovery with clinical development scenarios. Partnership bridges AI-powered molecule discovery capabilities with Tigermed's clinical execution expertise.
• TAYA Technology and Alibaba CloudcoreTechnology or Integration · 1 January 2026AI collaboration focused on large model operations and organizational efficiency. Partnership accelerates iteration of AI applications in clinical R&D through combined TAYA AI platform with Alibaba Cloud infrastructure.
• Multinational Pharmaceutical CompaniescoreStrategic or Co-development Partner · 1 January 2026Strategic collaboration for early-stage clinical development in China. Tigermed participates in strategic planning of global early-stage clinical research for leading multinational pharmaceutical company, reflecting growing international recognition of Tigermed's integrated platform.
• MedidatacoreTechnology or Integration · 1 January 2025Partnership extension for clinical research technology integration. Medidata's clinical trial technology platform integrated with Tigermed's CRO services to enhance clinical operations, data management, and digital trial capabilities.
• CanSino BiologicscoreStrategic or Co-development Partner · 1 September 2020Phase III clinical trial collaboration for Ad5-nCoV COVID-19 vaccine. Tigermed provided cross-country coordination and operations including project management, data management, biometrics, pharmacovigilance, and third-party audit. Successfully delivered first China-initiated Phase III vaccine trial covering Asia, Europe, and Latin America.

Scale indicators17 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Syneos Health: Global biopharmaceutical solutions organization (clinical + commercial). Comparable end-to-end clinical CRO services for global biopharma, though now privately held following Elliott/Veritas take-private.
• IQVIA: World's largest CRO with broad clinical, technology (e.g., EDC), and real-world evidence capabilities. Competes head-to-head with Tigermed on global MNC engagements and large Phase III programs, with deeper FDA/EMA relationships.
• ICON plc: Global top-3 CRO formed via PRA Health Sciences acquisition. Direct competitor on Phase II-IV clinical trials, FSP, and decentralized trial capabilities for multinational sponsors.
• Parexel International: Global CRO owned by EQT/Goldman Sachs offering clinical, regulatory, and post-approval services. Direct competitor for multinational pharma outsourcing mandates.
• Charles River Laboratories: Global CRO/preclinical specialist with strong discovery, safety assessment, and biologics capabilities. Comparable for preclinical/DMPK/safety services that overlap with Tigermed's preclinical franchise.
• Labcorp (incl. Covance): US-based diagnostics and clinical trials (Covance) business; broad incumbent offering central labs, early development, and clinical trial services comparable to Tigermed's integrated service portfolio.

Direct peers

• WuXi AppTec: China-headquartered, Hong Kong-listed CRO/CDMO offering preclinical, clinical, and laboratory services. Most directly comparable competitor in scale, geographic mix, and end-to-end CRO/CDMO positioning for global pharma.
• Medpace Holdings: Mid-size global CRO specializing in Phase II-IV clinical development with strong therapeutic-area focus (oncology, metabolic, rare disease). Comparable for mid-sized biopharma sponsors seeking full-service clinical execution.
• Pharmaron: China-headquartered, Hong Kong-listed CRO/CDMO with integrated drug discovery, preclinical, and clinical services. Direct competitor for both Chinese biotech sponsors and multinational pharma seeking China-based integrated CRO support.

Others

• Frontage Laboratories: Tigermed's majority-owned subsidiary (1521.HK) providing bioanalytical and laboratory services. Subsidiary/related party rather than competitor, but comparable as a standalone CRO/lab operator.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Tigermed_Group
• YouTubeyoutube.com/channel/UCUI32N_MF-Q1seqJ4cIquTg
• LinkedInlinkedin.cn/company/tigermed-consulting-ltd-/?viewAsMember=true

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries14 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments24 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tigermed